Avenue Therapeutics, Inc. is a specialty pharmaceutical company focused on developing drug product candidates. Its primary pipeline includes IV tramadol, an intravenous formulation of the analgesic tramadol, and ATX-04. The company has no approved products for commercial sale. It previously held rights to AJ201 (licensed from AnnJi Pharmaceutical) and BAER101 (via Baergic Bio), both of which have been divested. Avenue is a majority-controlled subsidiary of Fortress Biotech, Inc.
Q2 FY2026 — expected 2026-09-17
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-30 | 2025-12-31 | 0001437749-26-010359 | EDGAR | 85K words |
| 2025-03-31 | 2024-12-31 | 0001437749-25-010196 | EDGAR | — |
| 2024-03-18 | 2023-12-31 | 0001437749-24-008294 | EDGAR | — |
| 2023-03-31 | 2022-12-31 | 0001410578-23-000557 | EDGAR | — |
| 2022-03-25 | 2021-12-31 | 0001410578-22-000516 | EDGAR | — |
| 2021-03-31 | 2020-12-31 | 0001104659-21-044358 | EDGAR | — |
| 2020-03-30 | 2019-12-31 | 0001104659-20-040345 | EDGAR | — |
| 2019-03-12 | 2018-12-31 | 0001144204-19-013543 | EDGAR | — |
| 2018-03-01 | 2017-12-31 | 0001144204-18-012321 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-13 | 2025-09-30 | 0001437749-25-034821 | EDGAR | 21K words |
| 2025-08-14 | 2025-06-30 | 0001437749-25-026935 | EDGAR | — |
| 2025-05-15 | 2025-03-31 | 0001437749-25-017180 | EDGAR | — |
| 2024-11-14 | 2024-09-30 | 0001437749-24-035309 | EDGAR | — |
| 2024-08-09 | 2024-06-30 | 0001437749-24-025880 | EDGAR | — |
| 2024-05-15 | 2024-03-31 | 0001437749-24-017062 | EDGAR | — |
| 2023-11-13 | 2023-09-30 | 0001437749-23-031621 | EDGAR | — |
| 2023-08-11 | 2023-06-30 | 0001437749-23-023335 | EDGAR | — |
| 2023-05-12 | 2023-03-31 | 0001437749-23-014236 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0001410578-22-003151 | EDGAR | — |
| 2022-08-15 | 2022-06-30 | 0001410578-22-002605 | EDGAR | — |
| 2022-05-16 | 2022-03-31 | 0001410578-22-001659 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-02-23 | 0001104659-26-018582 | EDGAR | 1K words |
| 2025-12-31 | 0001104659-25-125420 | EDGAR | — |
| 2025-11-18 | 0001437749-25-035624 | EDGAR | — |
| 2025-11-12 | 0001437749-25-034243 | EDGAR | — |
| 2025-04-30 | 0001104659-25-042570 | EDGAR | — |
| 2025-03-17 | 0001104659-25-024505 | EDGAR | — |
| 2025-03-07 | 0001437749-25-006685 | EDGAR | — |
| 2024-11-29 | 0001104659-24-124081 | EDGAR | — |
| 2024-11-14 | 0001437749-24-035304 | EDGAR | — |
| 2024-09-27 | 0001437749-24-030185 | EDGAR | — |
188 total filings indexed. 157 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001644963 |
| Ticker | ATXI |
| Exchange | OTC |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report